Proteoglycan 4, a Novel Immunomodulatory Factor, Regulates Parathyroid Hormone Actions on Hematopoietic Cells

Chad M Novince; Amy J Koh; Megan N Michalski; Julie T Marchesan; Jason Wang; Younghun Jung; Janice E Berry; Matthew R Eber; Thomas J Rosol; Russell S Taichman; Laurie K McCauley

doi:10.1016/j.ajpath.2011.07.032

. 2011 Nov;179(5):2431–2442. doi: 10.1016/j.ajpath.2011.07.032

Proteoglycan 4, a Novel Immunomodulatory Factor, Regulates Parathyroid Hormone Actions on Hematopoietic Cells

Chad M Novince ^⁎, Amy J Koh ^⁎, Megan N Michalski ^⁎, Julie T Marchesan ^⁎, Jason Wang ^⁎, Younghun Jung ^⁎, Janice E Berry ^⁎, Matthew R Eber ^⁎, Thomas J Rosol ^†,^⁎, Russell S Taichman ^⁎, Laurie K McCauley ^⁎,^‡,^⁎

PMCID: PMC3204095 PMID: 21939632

Abstract

Proteoglycan 4 (PRG4), a critical protective factor in articular joints, is implicated in hematopoietic progenitor cell expansion and megakaryopoiesis. PRG4 loss-of-function mutations result in camptodactyly-arthropathy-coxa vara-pericarditis (CACP) syndrome, which is characterized primarily by precocious joint failure. PRG4 was identified as a novel parathyroid hormone (PTH) responsiveness gene in osteoblastic cells in bone, and was investigated as a potential mediator of PTH actions on hematopoiesis. Sixteen-week-old Prg4^−/− mutant and Prg4^+/+ wild-type mice were treated daily with intermittent PTH (residues 1–34) or vehicle for 6 weeks. At 22 weeks of age, Prg4 mutant mice had increased peripheral blood neutrophils and decreased marrow B220⁺ (B-lymphocytic) cells, which were normalized by PTH. The PTH-induced increase in marrow Lin⁻Sca-1⁺c-Kit⁺ (hematopoietic progenitor) cells was blunted in mutant mice. Basal and PTH-stimulated stromal cell-derived factor-1 (SDF-1) was decreased in mutant mice, suggesting SDF-1 as a candidate regulator of proteoglycan 4 actions on hematopoiesis in vivo. PTH stimulation of IL-6 mRNA was greater in mutant than in wild-type calvaria and bone marrow, suggesting a compensatory mechanism in the PTH-induced increase in marrow hematopoietic progenitor cells. In summary, proteoglycan 4 is a novel PTH-responsive factor regulating immune cells and PTH actions on marrow hematopoietic progenitor cells.

Parathyroid hormone (PTH), best known for its roles in calcium homeostasis and bone remodeling,¹ supports hematopoietic progenitor cell (HPC) expansion and mobilization.2, 3, 4 Although clinical investigations are assessing intermittent PTH administration as a potential stem cell therapy after bone marrow transplants,⁵ the mechanisms mediating PTH actions on hematopoiesis are poorly understood.

Stromal osteoblastic cells are the dominant cell type expressing PTH/PTH-related protein (PTHrP) receptor (PPR) in the bone marrow. With the exception of specific PPR-expressing T-cell subpopulations,6, 7 PTH actions on hematopoiesis are thought to be mediated via paracrine or juxtacrine signaling from PPR-activated stromal osteoblastic cells.1, 2, 8

PPR signaling in stromal osteoblastic cells alters the expression of osteoclastic cytokines, most notably receptor activator of nuclear factor-κB ligand (RANKL) and osteoprotegerin (OPG), which regulate the differentiation of hematopoietic cells to mature bone resorbing osteoclastic cells.8, 9, 10, 11, 12 More recent studies have focused on the role of PTH actions on HPCs. Calvi et al² demonstrated in mutant mice with osteoblast-specific constitutively active PPR that osteoblastic cells increase HPC expansion via Jagged1 ligand. Further investigation revealed that intermittent PTH administration in normal mice supported hematopoiesis through actions on early HPCs.² Ex vivo and in vivo PTH studies by Pirih et al¹³ using the global IL-6 knockout mouse model demonstrated that IL-6 supports PTH expansion of HPCs.

The proteoglycan 4 gene (human PRG4; murine Prg4), which has been implicated in HPC expansion14, 15, 16 and megakaryopoiesis,17, 18, 19 was identified as a novel PTH-responsive gene in bone.20, 21 The PRG4 gene encodes an approximately 345-kDa proteoglycan, consisting of 1404 amino acids spanning 12 exons. PRG4 is expressed across skeletal and nonskeletal tissues, with highest relative levels of expression in articular joints, liver, and bone.22, 23 The four isolated PRG4 protein products [ie, lubricin, superficial zone protein (SZP), hemangiopoietin (HAPO), and megakaryocyte stimulating factor (MSF)] are secreted glycoproteins that have been implicated in articular joint protection,23, 24 HPC expansion,¹⁴ and megakaryopoiesis¹⁷ (Table 1). A proteoglycan 4 receptor has not yet been identified.14, 23 Loss-of-function mutations in PRG4 result in the human autosomal recessive disorder known as camptodactyly-arthropathy-coxa vara-pericarditis syndrome (CACP), which is characterized by early-onset joint failure and osteopenia. CACP patients have not been reported to spontaneously develop hematological disorders.²⁵

Table 1.

PRG4 Protein Products

Protein product	Isolation	Expression	Known functions
Lubricin²³	Bovine synovial fluids	Synoviocytes	Boundary lubrication of synovial joints
Superficial zone protein (SZP)²⁴	Bovine superficial zone articular cartilage explant culture media	Superficial zone articular chondrocytes	Protects superficial zone articular cartilage
Hemangiopoietin (HAPO)¹⁴	Urine of patients afflicted by aplastic anemia	Unknown	Supports hematopoietic and endothelial progenitor cells
Megakaryocyte stimulating factor (MSF)¹⁷	Urine of bone marrow transfer patients afflicted by acute thrombocytopenia	Unknown	Regulates megakaryopoiesis

Open in a new tab

Although selected studies have reported that HAPO supports HPC expansion14, 15, 16 and that MSF regulates megakaryopoiesis,17, 18, 19 the actions of proteoglycan 4 on hematopoiesis are unclear. The purpose of the present study was to investigate the unexplored role of proteoglycan 4 as a regulator of physiological hematopoiesis and PTH actions on hematopoiesis in the mature skeleton. Using the Prg4-null mouse model,²³ we report the first known study of Prg4 actions on hematopoiesis in vivo.

Materials and Methods

C57BL/6 Wild-Type Mice, Single PTH Administration

Sixteen-week-old C57BL/6 wild-type mice were administered a single subcutaneous injection of recombinant human PTH residues 1 to 34 [PTH(1–34); 1 μg/g] (Bachem, Torrance, CA) or vehicle (0.9% NaCl) and then were sacrificed 4, 8, or 12 hours later; bone marrow was harvested for gene expression analysis. All animal studies were approved by the University Committee on the Use and Care of Animals (UCUCA) of the University of Michigan, and animals were maintained in accordance with approved UCUCA research protocols.

Primary Calvarial Osteoblastic Cell Cultures, Single PTH Administration

Primary osteoblasts were isolated from calvariae harvested from 7- to 14-day-old C57BL/6 wild-type mice. Briefly, calvariae were dissected, isolated from periosteum, and subjected to sequential digestion for 10, 20, and 60 minutes in α-modified minimum essential medium (Invitrogen, Carlsbad, CA) containing collagenase A (2 mg/mL) (Roche Molecular Biochemicals, Indianapolis, IN) and 0.25% trypsin (Invitrogen). Cells from the last digest were washed, counted, and plated at 5 × 10⁴/cm² in α-modified minimum essential medium with 10% fetal bovine serum (Invitrogen), 100 U/mL penicillin, 100 mg/mL streptomycin, and 2 mmol/L glutamine. Cells were induced to differentiate by supplementing medium with 50 μg/mL ascorbic acid.

Cultures at day 5 (d5) were administered a single recombinant human PTH(1–34) (10 nmol/L) (Bachem) or vehicle (4 mmol/L HCl/0.1%BSA) treatment and were harvested 8, 12, or 24 hours later for gene expression analysis. In another experimental protocol, d1, d5, d11, and d14 cultures were administered a single recombinant human PTH(1–34) (10 nmol/L) (Bachem) or vehicle (4 mmol/L HCl/0.1%BSA) treatment and were harvested 4 hours later for gene expression analysis.

Background of Prg4^−/− Mutant Mice

Prg4^−/− mutant mice with a mutant Prg4 allele generated by homologous recombination in 129Sv/Ev-derived embryonic stem cells were generously provided by Matthew Warman (Harvard University).²³ Mutant mice were backcrossed from the 129Sv/Ev genetic background to the C57BL/6 genetic background. A PCR-based assay was used to genotype the mice, as described previously.²³

Prg4^−/− Mutant Mice, Single PTH Administration

At 16 weeks of age, Prg4^−/− mutant and Prg4^+/+ wild-type littermate mice were administered a single subcutaneous injection of recombinant human PTH(1–34) (1 μg/g) (Bachem) or vehicle (0.9% NaCl) and then were sacrificed 1, 4, 8, or 12 hours later; bone marrow and calvariae were harvested for gene expression analysis.

Prg4^−/− Mutant Mice, 6 Weeks Daily Intermittent PTH Administration

In an intermittent PTH experimental protocol, 16-week-old Prg4^−/− mutant and Prg4^+/+ wild-type littermate mice were administered intermittent daily subcutaneous injection of recombinant human PTH(1–34) (50 μg/kg) (Bachem) or vehicle (0.9% NaCl) control for 6 weeks, to 22 weeks of age. Mice were sacrificed 24 hours after the final injection, and tissues were harvested for analyses.

Quantitative Real-Time PCR

Bone marrow was directly flushed from femur and tibia with TRIzol reagent (Invitrogen) using a 3-mL syringe and 22G ½-inch (∼12.7-mm length) needle. Calvariae were flash-frozen, pulverized, and homogenized in TRIzol reagent. Calvarial osteoblast cultures were washed three times with 1× PBS, and TRIzol was directly applied to cultures. In each case, RNA was isolated according to manufacturer's directions, and total RNA was quantified. Double-stranded cDNA was synthesized from 1.0 μg of RNA, using random hexamers and MultiScribe reverse transcriptase (Applied Biosystems, Foster City, CA). cDNA was amplified using the TaqMan universal PCR master mix with TaqMan gene expression-specific primers and probes (Applied Biosystems) for proteoglycan 4 (PRG4), interleukin-6 (IL-6), thrombopoietin (TPO), stromal cell-derived factor-1 (SDF-1), and osteocalcin (OCN). Rodent glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (Applied Biosystems) was used as an endogenous control. Amplification was performed using the ABI Prism 7700 sequence detection system (Applied Biosystems). Relative quantification of data were determined using the standard curve method or the comparative C_t method.²⁶

Complete Blood Counts

Whole blood was collected by cardiac puncture, transferred to Microtainer tubes with potassium-EDTA (BD Biosciences, San Jose, CA) and gently agitated. Complete blood count analysis (automated differential) was performed using a Hemavet 1500FS system (Drew Scientific, Waterbury, CT).

Flow Cytometry

Flushed femoral bone marrow cells and dissociated spleen cells were isolated, and all staining steps were performed using flow cytometry staining buffer (FCSB) (1× PBS, 2% fetal bovine serum, 2 mmol/L EDTA). Femurs were sectioned at the mid-diaphysis, a 22G ½-inch needle was gently rotated through the epiphysis into the marrow cavity, and marrow cells were flushed out from the sectioned mid-diaphysis with FCSB. Spleens were incised lengthwise, placed on a cell strainer, and disassociated with a 1-mL syringe plunger while FCSB was being delivered at the same time. Cell suspensions were homogenized, strained, centrifuged, and resuspended; cell counts were then performed. Three million cells were suspended in 0.5 mL FCSB, incubated with fluorochrome-conjugated antibodies (BD Biosciences) for 30 minutes at 4°C, and then were washed, centrifuged, and resuspended in 1 mL FCSB containing 7-AAD (Invitrogen) for analysis. All antibodies were from BD Biosciences. The frequency of CD11b⁺GR1⁺ (immature myeloid) cells, CD3⁺ (T-lymphocytic) cells, B220⁺ (B-lymphocytic) cells, Lin⁻Sca-1⁺c-Kit⁺ (hematopoietic progenitor) cells, and CD41⁺ (megakaryopoietic) cells were assessed in bone marrow. The frequency of B220⁺ cells was assessed in spleens. Samples were analyzed using a FACSCalibur flow cytometer and CellQuest Pro software version 5.1 (BD Biosciences).

A flow cytometry double-staining technique was used to assess megakaryocyte ploidy. Three million femoral bone marrow cells were suspended in 0.5 mL FCSB, incubated with FITC-conjugated CD41 antibody for 30 minutes at 4°C, rinsed with 1× PBS, centrifuged, and fixed in 1 mL 1% paraformaldehyde overnight at 4°C. Cells were centrifuged, washed with 1× PBS, resuspended in 1 mL propidium iodide staining solution (1× PBS, 4 mmol/L sodium citrate, 0.1% Triton X-100, 50 μg/mL propidium iodide, and 100 μg/mL RNase A), and incubated for 1 hour at 37°C. A minimum of 10,000 gated cells were analyzed for each sample. Samples were analyzed using a FACSCalibur flow cytometer and CellQuest Pro software version 5.1 (BD Biosciences).

Histomorphometry

Tibiae were fixed in 10% phosphate-buffered formalin for 48 hours at 4°C, dehydrated in graded ethanols and xylene, and embedded in modified methylmethacrylate. Frontal serial sections (4 μm) were cut with vertical bed microtomes (Jung 2065 and 2165; Leica Microsystems, Bannockburn, IL) and affixed to slides precoated with 1% gelatin solution. Sections were stained according to the von Kossa method with a tetrachrome counterstain (Polysciences, Warrington, PA), and used to enumerate megakaryocytes per marrow area. Histomorphometric data were collected semiautomatically with a Nikon light microscope and the OsteoMeasure trabecular analysis system (OsteoMetrics, Atlanta, GA).

Tibiae, liver (left lobe), and spleen were fixed in 10% phosphate-buffered formalin for 48 hours at 4°C. Tibiae were decalcified in 14% EDTA for 14 days at room temperature. Tibiae, liver, and spleen were embedded in paraffin, and 5-μm-thick serial sections were cut and stained. H&E staining was performed on all tissue sections.

SDF-1 immunofluorescence analysis was performed in proximal tibia sections. Samples were deparaffinized with mixed xylenes, rehydrated in graded ethanols, and then briefly washed with PBT (PBS-0.2% Triton X-100) and blocked for 30 minutes with Image-iT FX signal enhancer (Invitrogen). SDF-1 immunofluorescence analysis was performed using a Zenon AlexaFluor 488 rabbit labeling kit (Invitrogen) and SDF-1 α rabbit polyclonal antibody (ab25117; Abcam, Cambridge, MA). After overnight incubation at 4°C with 1 μg/100 μL dilution of fluorescence-labeled SDF-1 α rabbit polyclonal antibody (Abcam), sections were washed with PBT, mounted with ProLong Gold antifade reagent with DAPI (Invitrogen), and coverslipped. Images were acquired with an Olympus FV-500 confocal microscope. Image analysis of SDF-1 immunofluorescence in proximal tibia trabecular bone (secondary spongiosa) was performed using Image Pro Plus version 5.1 software (Media Cybernetics, Silver Spring, MD).

Bone Marrow Biochemical Studies

Bone marrow was directly flushed from femur and tibia with 1 mL 0.9% NaCl using a 1-mL syringe and a 22G ½-inch needle. The marrow suspension was homogenized and cell counts performed. Cell suspensions were centrifuged at 81.6 × g for 5 minutes, supernatants were collected, stored at −80°C, and freeze-thawed once. SDF-1 levels in the bone marrow supernatant were analyzed by antibody sandwich enzyme-linked immunosorbent assay (R&D Systems, Minneapolis, MN) according to the manufacturer's protocol, with a detection range of 62.5 to 10,000 pg/mL. SDF-1 levels were normalized to marrow cell numbers.

Statistical Analysis

Analysis of variance and unpaired t-test were performed using GraphPad Instat software version 3.10 (GraphPad Software, San Diego, CA). Statistical significance was set at P ≤ 0.05. Data are expressed as means ± SEM.

Results

Single PTH Administration Increases Prg4 mRNA Levels in Bone

Quantitative real-time PCR studies demonstrated that Prg4 is a novel PTH-responsiveness gene in bone, both in vivo and in vitro (Figure 1, A–C). A single subcutaneous injection of PTH(1–34) (1 μg/g) in 16-week-old C57BL/6 wild-type mice significantly increased Prg4 mRNA in bone marrow at 4 and 8 hours after injection (Figure 1A). Moreover, a single PTH(1–34) administration (10 nmol/L) to primary calvarial osteoblastic cell cultures significantly up-regulated Prg4 mRNA at 8, 12, and 24 hours after treatment (Figure 1B).

PTH regulation of *Prg4* mRNA. A: Sixteen-week-old C57BL/6 wild-type mice were administered a single subcutaneous injection of PTH(1–34) (1 μg/g) or vehicle (VEH) (0.9% NaCl) control and then were sacrificed 4, 8, or 12 hours later; bone marrow was harvested for *Prg4* mRNA expression analysis (n = 5 per group). *P < 0.05 versus VEH. B: C57BL/6 wild-type mouse-derived calvarial osteoblast cultures were administered a single treatment of PTH (10 nmol/L) or vehicle (VEH) (4 mmol/L HCl/0.1% SA) and were harvested 8, 12, or 24 hours later for *Prg4* mRNA expression analysis (n = 7 per group). *P < 0.01 versus VEH. C: C57BL/6 wild-type mouse-derived calvarial osteoblast cultures, 1, 5, 11, and 14 days after plating, were administered a single treatment of PTH (10 nmol/L) or vehicle (VEH) (4 mmol/L HCl/0.1%BSA) treatment and were harvested 4 hours later for *Prg4* mRNA expression analysis (n = 3 per group). *P < 0.05, PTH versus VEH; ^†P < 0.001, PTH versus VEH; ^‡P < 0.01, PTH versus VEH; ^§P < 0.01, d5-VEH versus d1-VEH; ^¶P < 0.05, d14-VEH versus d11-VEH. D: From the same cultures as in C, osteocalcin (OCN) mRNA expression was assessed as a marker of osteoblast differentiation. *P < 0.001, d11 versus d5; ^†P < 0.05, d14 versus d11. RNA was isolated and quantitative real-time PCR was performed to assess *Prg4* mRNA and OCN mRNA expression (standardized to GAPDH levels). Relative quantification of data generated was determined using the standard curve method. Data are expressed as means ± SEM.

Prg4 mRNA expression was evaluated in d1, d5, d11, and d14 primary calvarial osteoblastic cell cultures to elucidate the role of osteoblast maturation on basal and PTH-stimulated Prg4 mRNA expression. Basal Prg4 mRNA expression was highest in less differentiated osteoblastic cell cultures and significantly decreased with increasing differentiation over time (Figure 1C). At 4 hours, a single PTH administration significantly increased Prg4 mRNA at all stages of differentiation. Relative to vehicle-control samples, PTH significantly increased Prg4 mRNA at day 1 (1.5-fold), day 5 (2.8-fold), day 11 (5.3-fold), and day 14 (24.4-fold) (Figure 1C). Osteocalcin gene expression studies validated the maturation of osteoblastic cells in culture over time (Figure 1D), as we have previously reported.²⁷

Bone Marrow, Liver, and Spleen Morphology

Tibia, liver, and spleen were isolated after 6 weeks of PTH or vehicle treatment (ie, 22-week-old mice) for histological evaluation of hematopoietic organs (Figure 2, A–C). Proximal tibia marrow morphology was similar in 22-week-old Prg4^−/− and Prg4^+/+ mice (Figure 2A). Likewise, there were no morphological differences found in 22-week-old Prg4^−/− liver (Figure 2B) or spleen (Figure 2C) relative to Prg4^+/+ littermates, and no evidence of extramedullary hematopoiesis in these organs.

Histological assessment of bone marrow, liver, and spleen. *Prg4*^−/− mutant and *Prg4*^+/+ wild-type mice were administered intermittent PTH(1–34) (50 μg/kg) or vehicle (VEH) (0.9% NaCl) control subcutaneous injections daily for 6 weeks, from age 16 weeks to 22 weeks. Tibia, liver, and spleen were isolated from 22-week-old *Prg4*^−/− and *Prg4*^+/+ mice for histological evaluation. Images are representative images of H&E-stained proximal tibia bone marrow sections (n ≥ 10 per group) (A), liver sections (n ≥ 5 per group) (B), and spleen sections (n ≥ 5 per group) (C). Original magnification: ×40 (A and B); ×20 (C).

Bone Marrow IL-6, Thrombopoietin, and SDF-1 mRNA in Prg4^−/− Mice

Based on previous reports implicating the Prg4 protein products HAPO and MSF in HPC expansion14, 15, 16 and megakaryopoiesis,17, 18, 19 we evaluated the expression of several genes that are dual regulators of HPCs and megakaryopoiesis. Sixteen-week-old Prg4^−/− and Prg4^+/+ mice were administered a single subcutaneous injection of PTH(1–34) (1 μg/g) or vehicle (0.9% NaCl) control and then were sacrificed 1, 4, 8, or 12 hours later; bone marrow total RNA was isolated, and quantitative real-time PCR was performed to assess IL-6, TPO, and SDF-1 mRNA expression.

IL-6 is a pleiotropic factor with diverse biological roles, including the support of hematopoiesis, lymphopoiesis,28, 29 and megakaryopoiesis.30, 31 Marrow IL-6 mRNA levels were significantly lower in control 16-week-old Prg4^−/− mice and were consistently expressed at 60% of the levels detected in Prg4^+/+ littermates (Figure 3A). IL-6 is an immediate early-response gene up-regulated in bone in vitro and in vivo by PTH at 30 minutes to 1 hour after administration.32, 33, 34 IL-6 mRNA levels were significantly increased at 1 hour after PTH injection in 16-week-old Prg4^−/− and Prg4^+/+ marrow, returning to baseline at 4 hours. Relative to vehicle-control samples, PTH injection increased IL-6 mRNA to a significantly greater extent at 1 hour in Prg4^−/− marrow (13-fold) than in Prg4^+/+ marrow (fivefold) (P < 0.01) (Figure 3A).

PTH regulation of gene expression. A, C, and D: Sixteen-week-old *Prg4*^−/− mutant and *Prg4*^+/+ wild-type mice were administered a single subcutaneous injection of PTH(1–34) (1 μg/g) or vehicle (VEH) (0.9% NaCl) control and then were sacrificed 1, 4, 8, or 12 hours later; bone marrow was harvested for gene expression analysis (n = 5 per group). RNA was isolated and quantitative real-time PCR was performed to assess mRNA expression of IL-6 (A), TPO (C), and SDF-1 (D), standardized to GAPDH levels. Relative quantification of data was determined using the comparative C_t method. B: Sixteen-week-old *Prg4*^−/− and *Prg4*^+/+ mice were untreated or administered a single subcutaneous injection of PTH(1–34) (1 μg/g) and then were sacrificed 1 hour later; calvariae were harvested for gene expression analysis (n = 5 per group). RNA was isolated and quantitative real-time PCR was performed to assess IL-6 mRNA expression (standardized to GAPDH levels). Values are expressed as treatment over no treatment control within treatment groups. A: Marrow IL-6 mRNA fold change at 1 and 4 hours after PTH injection. *P < 0.05, −/− VEH versus +/+ VEH; ^†P < 0.001, +/+ PTH versus +/+ VEH; ^‡P < 0.001, −/− PTH versus −/− VEH. B: Calvarial IL-6 mRNA fold change at 1 hour after PTH injection. *P < 0.05, −/− PTH versus +/+ PTH. C: Marrow TPO mRNA fold change at 1, 4, 8, and 12 hours after PTH injection. D: Marrow SDF-1 mRNA fold change at 14, 8, and 12 hours after PTH injection. *P < 0.05, −/− VEH versus +/+ VEH; ^†P < 0.05, +/+ PTH versus +/+ VEH; ^‡P < 0.01, −/− PTH versus −/− VEH. Data are expressed as means ± SEM.

IL6 gene expression studies were performed in calvariae harvested from untreated and single PTH-treated 16-week-old Prg4^−/− and Prg4^+/+ mice to characterize the cellular target mediating the exacerbated PTH-induced increase in marrow IL-6 mRNA in Prg4^−/− mice. Relative to controls, PTH injection induced a significantly greater increase in calvarial IL-6 mRNA in Prg4^−/− (132-fold) than in Prg4^+/+ mice (45-fold) at 1 hour after treatment (P < 0.05), substantiating an osteoblast target (Figure 3B).

TPO, the primary factor regulating megakaryopoiesis, has been shown to support HPCs.³⁵ Marrow TPO mRNA expression was similar in control 16-week-old Prg4^−/− and Prg4^+/+ mice, and PTH did not alter marrow TPO mRNA levels in Prg4^−/− or Prg4^+/+ mice (Figure 3C).

SDF-1, a chemokine expressed at high levels by bone marrow stromal osteoblastic cells, regulates the homing and mobilization of marrow HPCs,36, 37 megakaryocyte progenitor cells,³⁸ and immune cell populations.39, 40 Although intermittent PTH treatment has been reported to increase SDF-1 mRNA expression in bone, in vitro and in vivo,⁴¹ little is known regarding the temporal effects of PTH on SDF-1 mRNA expression. At 4 hours after PTH injection, marrow SDF-1 mRNA levels were reduced similarly in 16-week-old Prg4^−/− and Prg4^+/+ mice. At 12 hours after PTH injection, marrow SDF-1 mRNA was significantly increased in Prg4^+/+ mice but PTH notably failed to increase marrow SDF-1 mRNA in Prg4^−/− mice (Figure 3D). Gene expression studies in calvariae harvested from untreated and single PTH-treated 16-week-old Prg4^−/− and Prg4^+/+ mice demonstrated no change in SDF-1 mRNA expression at 12 hours after treatment (data not shown).

Prg4^−/− Mice Have Altered Immune Cell Populations, Normalized by PTH

Whole blood was collected from 22-week-old PTH-treated and vehicle-treated Prg4^−/− and Prg4^+/+ mice, and complete blood count studies were performed to assess peripheral blood cell populations. There were no differences in red blood cell values or platelet numbers between Prg4^−/− and Prg4^+/+ mice (see Supplemental Table S1 at http://ajp.amjpathol.org). Prg4^−/− mice had altered peripheral white blood cells, including increased percentages of neutrophils and decreased percentages of lymphocytes (Figure 4, A and B; see also Supplemental Table S1 at http://ajp.amjpathol.org). Unexpectedly, PTH treatment normalized the frequency of peripheral blood neutrophils and lymphocytes in Prg4^−/− mice to the levels of Prg4^+/+ mice (Figure 4, A and B; see also Supplemental Table S1 at http://ajp.amjpathol.org). Analysis of absolute cell numbers revealed that Prg4^−/− mice had increased numbers of neutrophils that were normalized by PTH (Figure 4, C and D; see also Supplemental Table S1 at http://ajp.amjpathol.org).

Peripheral blood cell analyses. **A–D:***Prg4*^−/− mutant and *Prg4*^+/+ wild-type mice were administered intermittent PTH(1–34) (50 μg/kg) or vehicle (VEH) (0.9% NaCl) control subcutaneous injection daily for 6 weeks, from age 16 weeks to 22 weeks. Peripheral blood was isolated via cardiac puncture from 22-week-old *Prg4*^−/− and *Prg4*^+/+ mice and complete blood count analysis (automated differential) was performed to assess peripheral blood cell populations. n ≥ 10 per group. A: Percentage of neutrophils. *P < 0.001 versus +/+ VEH; ^†P < 0.01 versus −/− VEH. B: Percentage of lymphocytes. *P < 0.001 versus +/+ VEH; ^†P < 0.001 versus −/− VEH. C: Number of neutrophils. *P < 0.01 versus +/+ VEH; ^†P < 0.05 versus −/− VEH. D: Number of lymphocytes. Data are expressed as means ± SEM.

To elucidate whether differences in peripheral blood immune cells reflected changes in the marrow, femoral bone marrow was harvested from 22-week-old Prg4^−/− and Prg4^+/+ mice for flow cytometric analysis of CD11b⁺GR1⁺ (immature myeloid) cells, CD3⁺ (T-lymphocytic) cells, and B220⁺ (B-lymphocytic) cells. The frequency of marrow CD11b⁺GR1⁺ cells and CD3⁺ cells did not differ between Prg4^−/− and Prg4^+/+ mice (Figure 5, A and B; see also Supplemental Figure S1 at http://ajp.amjpathol.org). Similar to the peripheral blood lymphocyte findings, Prg4^−/− mice had a reduced percentage of marrow B220⁺ cells, which were normalized to levels of Prg4^+/+ mice with PTH treatment (Figure 5, C and D). Based on differences in peripheral blood lymphocytes and marrow B-lymphocytic cells, the frequency of B220⁺ cells was assessed in the spleen, a center for B-lymphopoiesis. The frequency of B220⁺ cells in spleen was similar in 22-week-old Prg4^−/− and Prg4^+/+ mice (Figure 5, C and E). PTH decreased the percentage of splenic B220⁺ cells in Prg4^+/+ mice, an effect that may be secondary to PTH actions supporting the expansion of HPCs in the spleen.⁴² These data suggest that proteoglycan 4 restricts peripheral blood neutrophil numbers, which does not appear to be secondary to an altered frequency of marrow immature myeloid cells. Moreover, these data indicate that proteoglycan 4 supports the frequency of marrow B-lymphocytic cells.

Bone marrow and spleen immune cell analyses. **A–D:***Prg4*^−/− mutant and *Prg4*^+/+ wild-type mice were administered intermittent PTH(1–34) (50 μg/kg) or vehicle (VEH) (0.9% NaCl) control subcutaneous injections daily for 6 weeks, from age 16 weeks to 22 weeks. The 22-week-old *Prg4*^−/− and *Prg4*^+/+ mice were sacrificed and femur bone marrow cells were isolated for flow cytometric analysis of CD11b⁺GR1⁺ (immature myeloid) cells (n ≥ 9 per group) (A), CD3⁺ (T-lymphocytic) cells (n ≥ 9 per group) (B), and B220⁺ (B-lymphocytic) cells (n ≥ 9 per group) (C and D). C and E: Spleen cells were isolated for flow cytometric analysis of B220⁺ cells (n ≥ 10 per group). C: B220⁺ marrow and spleen cells. *P < 0.05 versus +/+ VEH; ^†P < 0.05 versus −/− VEH. Data are expressed as means ± SEM. Percentages shown are relative to total cells in marrow (A, B, and D) or spleen (E).

Prg4^−/− Mice Have Decreased Expansion of Marrow HPCs Induced by PTH

Recombinant HAPO administration increased marrow HPCs in normal mice and accelerated marrow hematopoietic reconstitution in mice subjected to irradiation¹⁴ or high-dose chemotherapy.¹⁵ To investigate the effect of proteoglycan 4 on marrow HPCs, we assessed the frequency of marrow Lin⁻Sca-1⁺c-Kit⁺ (hematopoietic progenitor) cells in 22-week-old Prg4^−/− and Prg4^+/+ mice by flow cytometric analysis (Figure 6). The percentage of marrow Lin⁻Sca-1⁺c-Kit⁺ cells was similar in vehicle-treated Prg4^−/− and Prg4^+/+ mice. PTH increased the frequency of Lin⁻Sca-1⁺c-Kit⁺ cells in both Prg4^−/− and Prg4^+/+ marrow; however, this increase was blunted in Prg4^−/− mice relative to Prg4^+/+ littermates (Figure 6). These data suggest that proteoglycan 4 supports PTH actions increasing marrow HPCs.

Bone marrow hematopoietic progenitor cell analyses. *Prg4*^−/− mutant and *Prg4*^+/+ wild-type mice were administered intermittent PTH(1–34) (50 μg/kg) or vehicle (VEH) (0.9% NaCl) control subcutaneous injections daily for 6 weeks, from age 16 weeks to 22 weeks. Femur bone marrow cells were isolated from 22-week-old *Prg4*^−/− and *Prg4*^+/+ mice for flow cytometric analysis of Lin⁻Sca-1⁺c-Kit⁺ (hematopoietic progenitor) cells (n ≥ 6 per group). A: Representative dot plots of FITC/c-Kit (x axis) versus PE/Sca-1 (y axis) (gated for Lin⁻ cell population). B: Percentage of Lin⁻Sca-1⁺c-Kit⁺ cells, relative to total marrow cells. *P < 0.01 versus +/+ VEH; ^†P < 0.05 versus −/− VEH & +/+ PTH. Data are expressed as means ± SEM.

Marrow Megakaryopoiesis Is Similar in Prg4^−/− and Prg4^+/+ Mice

Although there are no reported MSF studies in vivo, administration of purified MSF in vitro has been suggested to support the formation of platelet forming cells.17, 18, 19 To elucidate the effect of proteoglycan 4 on megakaryopoiesis, the frequency of marrow CD41⁺ (megakaryopoietic) cells and megakaryocyte ploidy (a relative measure of megakaryocyte maturity) were evaluated in 22-week-old Prg4^−/− versus Prg4^+/+ mice via flow cytometric analysis. The frequency of marrow CD41⁺ (megakaryopoietic) cells and megakaryocyte ploidy were similar in Prg4^−/− and Prg4^+/+ mice (see Supplemental Figure S2, A and B at http://ajp.amjpathol.org). Numbers of megakaryocytes per marrow area in proximal tibia sections were similar in 22-week-old Prg4^−/− and Prg4^+/+ mice (see Supplemental Figure S2, C and D, at http://ajp.amjpathol.org). These findings indicate that proteoglycan 4 is not a critical regulator of marrow megakaryopoiesis in vivo.

Prg4^−/− Mice Have Altered Marrow IL-6 mRNA and SDF-1 Protein

Marrow IL-6 mRNA expression was measured in 22-week-old PTH-treated and vehicle-treated Prg4^−/− and Prg4^+/+ mice (Figure 7A), because IL-6 mRNA levels in control 16-week-old Prg4^−/− mice were decreased, relative to Prg4^+/+ littermates. Similar to the 16-week-old Prg4^−/− mice, control 22-week-old Prg4^−/− mice had decreased marrow IL-6 mRNA levels, compared with Prg4^+/+ littermates (Figure 7A). These data suggest that Prg4 signaling supports basal IL-6 mRNA expression in the bone marrow.

Bone marrow IL-6 and SDF-1 expression. **A–E:***Prg4*^−/− mutant and *Prg4*^+/+ wild-type mice were administered intermittent PTH(1–34) (50 μg/kg) or vehicle (VEH) (0.9% NaCl) control subcutaneous injections daily for 6 weeks, from age 16 weeks to 22 weeks. A and B: Bone marrow was harvested from 22-week-old *Prg4*^−/− and *Prg4*^+/+ mice (n = 5 per group) for quantitative real-time PCR analysis of IL-6 (A) and SDF-1 (B) mRNA expression, standardized to GAPDH levels. Relative quantification of data was performed using the comparative C_t method. A: Marrow IL-6 mRNA expression. *P < 0.05 versus +/+ VEH. B: Marrow SDF-1 mRNA expression. C and D: SDF-1 immunofluorescence analysis was performed on proximal tibia (secondary spongiosa) sections of 22-week-old mice (n = 6 per group). C: Representative SDF-1 immunofluorescence-labeled proximal tibia sections (green, SDF-1; blue, DAPI); **arrows** indicate selected SDF-1⁺ stromal osteoblastic cells. Original magnification, ×60. D: SDF-1 area/DAPI area. *P < 0.001 versus +/+ VEH; ^†P < 0.01 versus +/+ VEH; ^‡P < 0.05 versus −/− VEH & +/+ PTH. E: ELISA analysis of bone marrow SDF-1 levels in 22-week-old *Prg4* mice, showing marrow SDF-1 (pg/mL) normalized to marrow cell numbers (n ≥ 5 per group). *P < 0.05, versus +/+ VEH; ^†P < 0.05, versus +/+ VEH; ^‡P < 0.05, versus −/− VEH & +/+ PTH. Data are expressed as means ± SEM.

Based on the findings that 22-week-old Prg4^−/− mice have increased numbers of peripheral neutrophils, decreased frequency of marrow B-lymphocytes, and a blunted PTH-induced increase in marrow HPC frequency, we assessed marrow SDF-1 mRNA and protein expression in 22-week-old Prg4^−/− versus Prg4^+/+ mice. Quantitative real-time PCR analysis demonstrated similar marrow SDF-1 mRNA levels in Prg4^−/− and Prg4^+/+ mice (Figure 7B), which indicates that Prg4 does not affect basal SDF-1 mRNA expression in the marrow. SDF-1 immunofluorescence analysis in proximal tibia (Figure 7, C and D) and SDF-1 ELISA analysis of hindlimb marrow (Figure 7E) demonstrated that SDF-1 protein was reduced in the marrow of Prg4^−/− mice, compared with Prg4^+/+ mice. PTH significantly increased SDF-1 protein expression in the marrow of Prg4^−/− and Prg4^+/+ mice; however, this was blunted in Prg4^−/− mice relative to Prg4^+/+ littermates (Figure 7, C–E). These data indicate that proteoglycan 4 supports basal marrow SDF-1 protein expression and the ability of PTH to increase SDF-1 protein expression in the bone marrow.

Discussion

Prg4 expression in the bone marrow of the mature skeleton suggests that proteoglycan 4 may affect adult hematopoiesis. That basal Prg4 mRNA expression was higher in less differentiated osteoblastic cell cultures suggests that more immature osteoblastic cells are a primary source of proteoglycan 4 in the bone marrow. Considering that more immature osteoblastic cells have been implicated in HPC expansion and function,⁴³ the finding that basal Prg4 mRNA expression is higher in less differentiated osteoblastic cell cultures suggests that proteoglycan 4 may be involved in the mechanism by which more immature osteoblastic cells support HPCs.

The in vivo PTH-induced increase in bone marrow Prg4 mRNA indicates that proteoglycan 4 could be a mediator of PTH biological actions in marrow hematopoiesis. Based on the PTH-induced increase in Prg4 mRNA in isolated osteoblastic cell cultures, we speculate that direct PTH signaling at PPR-expressing osteoblastic cells increases proteoglycan 4 secretion in the marrow, mediating paracrine signaling to hematopoietic cells. The finding that PTH increased Prg4 mRNA to consistently high levels in differentiated osteoblastic cell cultures, despite the lower basal levels, may simply reflect the greater PPR activity in more differentiated osteoblastic cells.²⁷

The dysregulated immune cell populations noted in Prg4 mutant mice may be secondary to the decreased basal expression of marrow SDF-1 protein and marrow IL-6 mRNA. Marrow and peripheral neutrophils express the SDF-1 receptor CXCR4 and have been shown to biologically respond to SDF-1.39, 44, 45, 46 Studies have demonstrated that the CXCR4/SDF-1 chemokine axis regulates circulating neutrophil homeostasis.39, 40, 47 Injection of CXCR4-blocking antibody in mice mobilized neutrophils from the marrow,³⁹ and drugs targeting CXCR4 induced a peripheral neutrophilia in mice and humans.⁴⁷ Because the Prg4 mutant mouse does not display signs of acute inflammation, which would induce the mobilization of immature neutrophils from the marrow into circulation, we speculate that decreased marrow SDF-1 disrupts the neutrophil CXCR4/SDF-1 axis, resulting in increased circulating neutrophils in the Prg4 mutant mouse.

The decreased frequency of peripheral blood lymphocytes in Prg4 mutant mice appears to be secondary to increased absolute numbers of peripheral blood neutrophils. Nevertheless, the frequency of marrow B-lymphocytic cells was significantly decreased in Prg4 mutant mice. Although the slight decrease in Prg4 mutant marrow B220⁺ cells implies that proteoglycan 4 is not a critical regulator of marrow B-lymphocyte cell numbers under normal physiological conditions, proteoglycan 4 actions supporting B220⁺ cell numbers may play a more crucial role during immune response.

The decreased expression of marrow SDF-1 protein in Prg4 mutant mice may contribute to the reduced frequency of marrow B-lymphocytic cells. B-lymphocyte progenitor cells express the CXCR4 receptor at high levels.48, 49 Mice deficient in SDF-1 have severely reduced B-lymphocyte progenitors in the marrow,50, 51 and studies have demonstrated that SDF-1 supports the homing40, 48, 49 and proliferation⁵² of marrow B-lymphocyte progenitors. Furthermore, reduced marrow IL-6 mRNA expression in Prg4 mutant mice may contribute to decreased frequency of B-lymphocytic cells, because IL-6 supports physiological B-lymphopoiesis.28, 53, 54 Similar to Prg4 mutant mice, mice with an osteoprogenitor cell G_sα deficiency (a downstream mediator of the PPR) have decreased peripheral blood and marrow B-lymphocytic cells,⁵⁵ suggesting that osteoblast cell signaling also could play a role in Prg4 mutant mice. The unexpected finding that PTH induced normalization of peripheral blood neutrophils and marrow B-lymphocytic cells in Prg4 mutant mice to wild-type levels may be associated with the PTH-induced increase in marrow SDF-1 protein in Prg4 mutant mice.

The similar frequency of marrow Lin⁻Sca-1⁺c-Kit⁺ cells in Prg4 mutant and wild-type mice suggests that proteoglycan 4 is not a critical regulator of physiological marrow HPC numbers. The finding that PTH increased Lin⁻Sca-1⁺c-Kit⁺ cells significantly more in Prg4 wild-type mice indicates that proteoglycan 4 supports PTH actions on HPC expansion. We speculate that, although basal proteoglycan 4 expression does not affect HPC numbers, the PTH-induced increase in proteoglycan 4 supports HPC expansion, a concept that is supported by HAPO studies.14, 15 Daily intermittent subcutaneous injection of recombinant HAPO in normal mice increases marrow HPC populations, including CD34⁺, c-Kit⁺, and Sca-1⁺ cells.¹⁴ Because SDF-1 is a potent chemoattractant that regulates the homing and mobilization of marrow HPC cells,36, 37, 56, 57 the blunted ability of PTH to increase SDF-1 in the marrow of Prg4 mutant mice may be linked to the blunted PTH expansion of marrow HPCs in Prg4 mutant mice.

PTH increased bone marrow and calvarial IL-6 mRNA to a greater extent in Prg4 mutant mice; thus, in the absence of Prg4, PTH differentially regulates the expression of PTH response-associated genes, which may represent an attempt at compensation for the absence of proteoglycan 4. IL-6 supports HPC proliferation,28, 29, 58, 59 and we have recently shown it to be a critical regulator of PTH actions in HPC expansion.¹³

Because the calvarial organ is composed primarily of stromal osteoblastic cells, the predominant PPR-expressing cell population in the bone marrow, the more significantly increased PTH-induced IL-6 mRNA in Prg4 mutant calvaria suggests that a stromal osteoblastic cell is the target of PTH actions to modulate IL-6 and hematopoietic cells in the marrow of Prg4 mutant mice. Because PTH modulated other responsiveness genes similarly in both Prg4 mutant and wild-type mice, the heightened IL-6 regulation in Prg4 mutant mice points to the likelihood of a specific compensatory effect occurring with the loss of proteoglycan 4 activity.

Although it has been reported that the Prg4 protein product MSF stimulates the growth of platelet forming cells in vitro,17, 18, 19 the similar number of peripheral blood platelets, similar frequency of marrow CD41⁺ cells, similar marrow megakaryocyte ploidy, and similar number of megakaryocytes per marrow area in Prg4 mutant and wild-type mice all suggest that proteoglycan 4 is not a critical regulator of physiological megakaryopoiesis in vivo.

PRG4 actions on SDF-1 are unknown. The decreased SDF-1 protein levels in the marrow of Prg4 mutant mice imply that proteoglycan 4 may interact with and increase the concentration of SDF-1 in the marrow. This is supported by prior studies, which have demonstrated that SDF-1 binds cellular proteoglycans in the bone marrow.60, 61, 62, 63, 64 A single PTH injection significantly increased SDF-1 mRNA in the marrow of wild-type but not mutant mice, which may explain the blunted increase in marrow SDF-1 protein levels in PTH-treated Prg4 mutant mice. In the light of recent work demonstrating that intermittent PTH administration inhibits dipeptidyl peptidase-IV (DPP-IV),⁶⁵ an enzyme that functionally degrades SDF-1, an alternative explanation for the blunted PTH increase in marrow SDF-1 is that PTH actions protecting marrow SDF-1 from enzymatic degradation are decreased in Prg4 mutant mice.

The present investigation of Prg4 actions on hematopoiesis revealed that proteoglycan 4 regulates marrow SDF-1 levels, immune cell populations, and PTH actions increasing marrow SDF-1 and HPCs. SDF-1 is a candidate regulator of proteoglycan 4 actions on hematopoiesis. Contrary to findings from other studies in which proteoglycan 4 was administered, characterization of the Prg4 mutant mouse model demonstrates that basal proteoglycan 4 expression does not affect megakaryopoiesis or HPC frequency. Although CACP patients have not been reported to spontaneously develop peripheral hematological abnormalities, we are unaware of any studies that characterize their bone marrow cell populations. The present study reveals that loss-of-function mutations in Prg4 may result in altered immune cell populations, some of which are compensated for but which could also have implications for immune response. In summary, proteoglycan 4 is a novel immunomodulatory factor regulating physiological immune cell populations and PTH actions on hematopoiesis.

Acknowledgments

We thank Dr. Matthew Warman for providing the Prg4 mutant mice, Dr. Hedwig Murphy for scientific discussions, and Chris Strayhorn and Payam Entezami for assistance with histological procedures.

Footnotes

Supported by NIH grants DE019395 (L.K.M.), DK53904 (L.K.M.), DE007057 (University of Michigan-T32), and DE021298 (C.M.N.-F30).

Supplemental material for this article can be found at http://ajp.amjpathol.org or at doi: 10.1016/j.ajpath.2011.07.032.

Supplementary data

Supplemental Table S1

mmc1.doc^{(37.5KB, doc)}

Supplemental Figure S1

Flow cytometry analysis of bone marrow immune cells. A and B:Prg4^−/− mutant and Prg4^+/+ wild-type mice were administered intermittent PTH(1–34) (50 μg/kg) or vehicle (VEH) (0.9% NaCl) control subcutaneous injections daily for 6 weeks, from age 16 weeks to 22 weeks. Femur bone marrow cells were isolated from 22-week-old Prg4^−/− and Prg4^+/+ mice for flow cytometric analysis of CD11b⁺GR1⁺ (immature myeloid) cells (n ≥ 9 per group) (A) and CD3⁺ (T-lymphocytic) cells (n ≥ 9 per group) (B). A: Representative dot plots of FITC/CD11b (x axis) versus PE/GR1 (y axis). B: Representative histograms for CD3⁺ marrow cells.

mmc2.pdf^{(248.5KB, pdf)}

Supplemental Figure S2

Bone marrow megakaryopoietic cell analyses. Prg4^−/− mutant and Prg4^+/+ wild-type mice were administered intermittent PTH (1–34) (50 μg/kg) or vehicle (VEH) (0.9% NaCl) control subcutaneous injections daily for 6 weeks, from age 16 weeks to 22 weeks. A: Flow cytometric analysis of CD41⁺ (megakaryopoietic) cells in femur bone marrow from 22-week-old Prg4^−/− and Prg4^+/+ mice (n ≥ 8 per group). *P < 0.05 versus −/− VEH. Percentages are relative to total marrow cells. B: Flow cytometric analysis of megakaryocyte ploidy from bone marrow of 22-week-old Prg4^−/− and +/+ mice (n ≥ 7 per group). *P < 0.001 versus +/+ VEH; ^†p<0.001 versus −/− VEH. Percentages are relative to cells within 8N, 16N, 32N ploidy classes. C: Representative images of proximal tibia sections from 22-week-old Prg4^−/− and Prg4^+/+ mice, with von Kossa staining and tetrachrome counterstain; megakaryocytes are highlighted by orange ellipses. Original magnification, ×20. D: Number of megakaryocytes per marrow area (n ≥ 9 per group). Data are expressed as means ± SEM.

mmc3.pdf^{(93.3KB, pdf)}

References

1.Kousteni S., Bilezikian J.P. In: Principles of Bone Biology. ed 3. Bilezikian J.P., Raisz L.G., Martin T.J., editors. 2008. Cellular actions of parathyroid hormone; pp. 639–656. [Google Scholar]
2.Calvi L.M., Adams G.B., Welbrecht K.W., Weber J.M., Olson D.P., Knight M.C., Martin R.P., Schipani E., Divieti P., Bringhurst F.R., Milner L.A., Kronenberg H.M., Scadden D.T. Osteoblastic cells regulate the haematopoietic stem cell niche. Nature. 2003;425:841–846. doi: 10.1038/nature02040. [DOI] [PubMed] [Google Scholar]
3.Brunner S., Zaruba M., Huber B., David R., Vallaster M., Assmann G., Mueller-Hoecker J., Franz W.M. Parathyroid hormone effectively induces mobilization of progenitor cells without depletion of bone marrow. Exp Hematol. 2008;36:1157–1166. doi: 10.1016/j.exphem.2008.03.014. [DOI] [PubMed] [Google Scholar]
4.Adams G.B., Martin R.P., Alley I.R., Chabner K.T., Cohen K.S., Calvi L.M., Kronenberg H.M., Scadden D.T. Therapeutic targeting of a stem cell niche. Nat Biotechnol. 2007;25:238–243. doi: 10.1038/nbt1281. [Erratum appeared in Nat Biotechnol 2007, 25:944, and in Nat Biotechnol 2008, 26:241] [DOI] [PubMed] [Google Scholar]
5.Ballen K.K., Shpall E.J., Avigan D., Yeap B.Y., Fisher D.C., McDermott K., Dey B.R., Attar E., McAfee S., Konopleva M., Antin J.H., Spitzer T.R. Phase I trial of parathyroid hormone to facilitate stem cell mobilization. Biol Blood Marrow Transplant. 2007;13:838–843. doi: 10.1016/j.bbmt.2007.03.007. [DOI] [PubMed] [Google Scholar]
6.McCauley L.K., Rosol T.J., Merryman J.I., Capen C.C. Parathyroid hormone-related protein binding to human T-cell lymphotropic virus type-I-infected lymphocytes. Endocrinology. 1992;130:300–306. doi: 10.1210/endo.130.1.1309334. [DOI] [PubMed] [Google Scholar]
7.Terauchi M., Li J.Y., Bedi B., Baek K.H., Tawfeek H., Galley S., Gilbert L., Nanes M.S., Zayzafoon M., Guldberg R., Lamar D.L., Singer M.A., Lane T.F., Kronenberg H.M., Pacifici R. T lymphocytes amplify the anabolic activity of parathyroid hormone through Wnt10b signaling. Cell Metab. 2009;10:229–240. doi: 10.1016/j.cmet.2009.07.010. [DOI] [PMC free article] [PubMed] [Google Scholar]
8.Li X., Liu H., Qin L., Tamasi J., Bergenstock M., Shapses S., Feyen J.H., Notterman D.A., Partridge N.C. Determination of dual effects of parathyroid hormone on skeletal gene expression in vivo by microarray and network analysis. J Biol Chem. 2007;282:33086–33097. doi: 10.1074/jbc.M705194200. [DOI] [PubMed] [Google Scholar]
9.Ma Y.L., Cain R.L., Halladay D.L., Yang X., Zeng Q., Miles R.R., Chandrasekhar S., Martin T.J., Onyia J.E. Catabolic effects of continuous human PTH (1–38) in vivo is associated with sustained stimulation of RANKL and inhibition of osteoprotegerin and gene-associated bone formation. Endocrinology. 2001;142:4047–4054. doi: 10.1210/endo.142.9.8356. [DOI] [PubMed] [Google Scholar]
10.Locklin R.M., Khosla S., Turner R.T., Riggs B.L. Mediators of biphasic responses of bone to intermittent and continuously administered parathyroid hormone. J Cell Biochem. 2003;89:180–190. doi: 10.1002/jcb.10490. [DOI] [PubMed] [Google Scholar]
11.Silvestrini G., Ballanti P., Leopizzi M., Gualtieri N., Sardella D., Monnazzi P., Simeoni S., Sebastiani M., Bonucci E., Patacchioli F.R. Effects of the administration of corticosterone, parathyroid hormone, or both, and of their withdrawal, on rat bone and cartilage histomorphometric parameters, and on osteoprotegerin and RANKL mRNA expression and proteins. J Mol Histol. 2007;38:215–226. doi: 10.1007/s10735-007-9090-9. [DOI] [PubMed] [Google Scholar]
12.Lee S.K., Lorenzo J.A. Parathyroid hormone stimulates TRANCE and inhibits osteoprotegerin messenger ribonucleic acid expression in murine bone marrow cultures: correlation with osteoclast-like cell formation. J Bone Miner Res. 1999;140:3552–3561. doi: 10.1210/endo.140.8.6887. [DOI] [PubMed] [Google Scholar]
13.Pirih F.Q., Michalski M.N., Cho S.W., Koh A.J., Berry J.E., Ghaname E., Kamarajan P., Bonnelye E., Ross C.W., Kapila Y.L., Jurdic P., McCauley L.K. Parathyroid hormone mediates hematopoietic cell expansion through interleukin-6. PLoS One. 2010;5:e13657. doi: 10.1371/journal.pone.0013657. [DOI] [PMC free article] [PubMed] [Google Scholar]
14.Liu Y.J., Lu S.H., Xu B., Yang R.C., Ren Q., Liu B., Li B., Lu M., Yan F.Y., Han Z.B., Han Z.C. Hemangiopoietin, a novel human growth factor for the primitive cells of both hematopoietic and endothelial cell lineages. Blood. 2004;103:4449–4456. doi: 10.1182/blood-2003-06-1825. [DOI] [PubMed] [Google Scholar]
15.Xu Z.L., Zhou B., Cong X.L., Liu Y.J., Xu B., Li Y.H., Gu J., Han Z.C. Hemangiopoietin supports animal survival and accelerates hematopoietic recovery of chemotherapy-suppressed mice. Eur J Haematol. 2007;79:477–485. doi: 10.1111/j.1600-0609.2007.00969.x. [DOI] [PubMed] [Google Scholar]
16.Xu Z.S., Liu Y.J., Lv L.L., Han Z.B., He R., Lu S.H., Wang T., Xu B., Chen Z.Z., Han Z.C. Bone marrow stromal cells transduced with human hemangiopoietin gene support hematopoiesis in vitro. Haematologica. 2005;90:157–165. [PubMed] [Google Scholar]
17.Merberg D.M., Fitz L.J., Temple P., Giannotti J., Murtha P., Fitzgerald M., Scaltreto H., Kelleher K., Preissner K., Kriz R., Jacobs K., Turner K. In: Biology of Vitronectins and Their Receptors: Proceedings of the First International Vitronectin Workshop, Rauischholzhausen Castle, Marburg, Germany, 25–28 August, 1993. Preissner K.T., Rosenblatt S., Kost C., Wegerhoff J., Mosher D.F., editors. Elsevier; Philadelphia: 1992. A comparison of vitronectin and megakaryocyte stimulating factor; pp. 45–53. [Google Scholar]
18.Greenberg S.M., Kuter D.J., Rosenberg R.D. In vitro stimulation of megakaryocyte maturation by megakaryocyte stimulatory factor. J Biol Chem. 1987;262:3269–3277. [PubMed] [Google Scholar]
19.Tayrien G., Rosenberg R.D. Purification and properties of a megakaryocyte stimulatory factor present both in the serum-free conditioned medium of human embryonic kidney cells and in thrombocytopenic plasma. J Biol Chem. 1987;262:3262–3268. [PubMed] [Google Scholar]
20.Novince C.M., Koh A.J., Marchesan J.T., McCauley L.K. Proteoglycan-4: a novel gene regulating parathyroid hormone actions in bone anabolism and hematopoiesis (abstract 1186): ASBMR 31st Annual Meeting 1001–1300. J Bone Miner Res. 2009;24:S56–S57. [Google Scholar]
21.Novince C.M., Michalski M.N., Sinder B.P., Entezami P., Koh A.J., Eber M.J., Pettway G.J., Rosol T.J., Wronski T.J., Kozloff K.M., McCauley L.K. J Bone Miner Res. 2011. Proteoglycan 4: a dynamic regulator of skeletogenesis and PTH skeletal anabolism. [DOI] [PMC free article] [PubMed] [Google Scholar]
22.Ikegawa S., Sano M., Koshizuka Y., Nakamura Y. Isolation, characterization and mapping of the mouse and human PRG4 (proteoglycan 4) genes. Cytogenet Genome Res. 2000;90:291–297. doi: 10.1159/000056791. [DOI] [PubMed] [Google Scholar]
23.Rhee D.K., Marcelino J., Baker M., Gong Y., Smits P., Lefebvre V., Jay G.D., Stewart M., Wang H., Warman M.L., Carpten J.D. The secreted glycoprotein lubricin protects cartilage surfaces and inhibits synovial cell overgrowth. J Clin Invest. 2005;115:622–631. doi: 10.1172/JCI200522263. [DOI] [PMC free article] [PubMed] [Google Scholar]
24.Schumacher B.L., Block J.A., Schmid T.M., Aydelotte M.B., Kuettner K.E. A novel proteoglycan synthesized and secreted by chondrocytes of the superficial zone of articular cartilage. Arch Biochem Biophys. 1994;311:144–152. doi: 10.1006/abbi.1994.1219. [DOI] [PubMed] [Google Scholar]
25.Marcelino J., Carpten J.D., Suwairi W.M., Gutierrez O.M., Schwartz S., Robbins C., Sood R., Makalowska I., Baxevanis A., Johnstone B., Laxer R.M., Zemel L., Kim C.A., Herd J.K., Ihle J., Williams C., Johnson M., Raman V., Alonso L.G., Brunoni D., Gerstein A., Papadopoulos N., Bahabri S.A., Trent J.M., Warman M.L. CACP, encoding a secreted proteoglycan, is mutated in camptodactyly-arthropathy-coxa vara-pericarditis syndrome. Nat Genet. 1999;23:319–322. doi: 10.1038/15496. [DOI] [PubMed] [Google Scholar]
26.Schmittgen T.D., Livak K.J. Analyzing real-time PCR data by the comparative CT method. Nat Protocols. 2008;3:1101–1108. doi: 10.1038/nprot.2008.73. [DOI] [PubMed] [Google Scholar]
27.McCauley L.K., Koh A.J., Beecher C.A., Cui Y., Decker J.D., Francheschi R.T. Effects of differentiation and transforming growth factor beta on PTH/PTHrP receptor mRNA levels in MC3T3-E1 cells. J Bone Miner Res. 1995;10:1243–1255. doi: 10.1002/jbmr.5650100815. [DOI] [PubMed] [Google Scholar]
28.Kopf M., Ramsay A., Brombacher F., Baumann H., Freer G., Galanos C., Gutierrez-Ramos J.C., Köhler G. Pleiotropic defects of IL-6-deficient mice including early hematopoiesis: T and B cell function, and acute phase responses. Ann N Y Acad Sci. 1985;21:308–318. doi: 10.1111/j.1749-6632.1995.tb32335.x. [DOI] [PubMed] [Google Scholar]
29.Ikebuchi K., Wong G.G., Clark S.C., Ihle J.N., Hirai Y., Ogawa M. Interleukin 6 enhancement of interleukin 3-dependent proliferation of multipotential hemopoietic progenitors. Proc Natl Acad Sci USA. 1987;84:9035–9039. doi: 10.1073/pnas.84.24.9035. [DOI] [PMC free article] [PubMed] [Google Scholar]
30.Imai T., Koike K., Kubo T., Kikuchi T., Amano Y., Takagi M., Okumura N., Nakahata T. Interleukin-6 supports human megakaryocytic proliferation and differentiation in vitro. Blood. 1991;78:1969–1974. [PubMed] [Google Scholar]
31.Hill R.J., Warren M.K., Stenberg P., Levin J., Corash L., Drummond R., Baker G., Levin F., Mok Y. Stimulation of megakaryocytopoiesis in mice by human recombinant interleukin-6. Blood. 1991;77:42–48. [PubMed] [Google Scholar]
32.Greenfield E.M., Gornik S.A., Horowitz M.C., Donahue H.J., Shaw S.M. Regulation of cytokine expression in osteoblasts by parathyroid hormone: rapid stimulation of interleukin-6 and leukemia inhibitory factor mRNA. J Bone Miner Res. 1993;8:1163–1171. doi: 10.1002/jbmr.5650081003. [DOI] [PubMed] [Google Scholar]
33.Onyia J.E., Bidwell J., Herring J., Hulman J., Hock J.M. In vivo, human parathyroid hormone fragment (hPTH 1-34) transiently stimulates immediate early response gene expression, but not proliferation, in trabecular bone cells of young rats. Bone. 1995;17:479–484. doi: 10.1016/8756-3282(95)00332-2. [DOI] [PubMed] [Google Scholar]
34.Pollock J.H., Blaha M.J., Lavish S.A., Stevenson S., Greenfield E.M. In vivo demonstration that parathyroid hormone and parathyroid hormone-related protein stimulate expression by osteoblasts of interleukin-6 and leukemia inhibitory factor. J Bone Miner Res. 1996;11:754–759. doi: 10.1002/jbmr.5650110606. [DOI] [PubMed] [Google Scholar]
35.Murone M., Carpenter D.A., de Sauvage F.J. Hematopoietic deficiencies in c-mpl and TPO knockout mice. Stem Cells. 1998;16:1–6. doi: 10.1002/stem.160001. [DOI] [PubMed] [Google Scholar]
36.Peled A., Petit I., Kollet O., Magid M., Ponomaryov T., Byk T., Nagler A., Ben-Hur H., Many A., Shultz L., Lider O., Alon R., Zipori D., Lapidot T. Dependence of human stem cell engraftment and repopulation of NOD/SCID mice on CXCR4. Science. 1999;283:845–848. doi: 10.1126/science.283.5403.845. [DOI] [PubMed] [Google Scholar]
37.Jo D.Y., Rafii S., Hamada T., Moore M.A. Chemotaxis of primitive hematopoietic cells in response to stromal cell-derived factor-1. J Clin Invest. 2000;105:101–111. doi: 10.1172/JCI7954. [DOI] [PMC free article] [PubMed] [Google Scholar]
38.Wang J.F., Liu Z.Y., Groopman J.E. The alpha-chemokine receptor CXCR4 is expressed on the megakaryocytic lineage from progenitor to platelets and modulates migration and adhesion. Blood. 1998;92:756–764. [PubMed] [Google Scholar]
39.Suratt B.T., Petty J.M., Young S.K., Malcom K.C., Lieber J.A., Nick J.A., Gonzalo J.A., Henson P.M., Worthen G.S. Role of the CXCR4/SDF-1 chemokine axis in circulating neutrophil homeostasis. Blood. 2004;104:565–571. doi: 10.1182/blood-2003-10-3638. [DOI] [PubMed] [Google Scholar]
40.Ma Q., Jones D., Springer T.A. The chemokine receptor CXCR4 is required for the retention of B lineage and granulocytic precursors within the bone marrow microenvironment. Immunity. 1999;10:463–471. doi: 10.1016/s1074-7613(00)80046-1. [DOI] [PubMed] [Google Scholar]
41.Jung Y., Wang J., Schneider A., Sun Y.X., Koh-Paige A.J., Osman N.I., McCauley L.K., Taichman R.S. Regulation of SDF-1 (CXCL12) production by osteoblasts in the hematopoietic microenvironment and a possible mechanism for stem cell homing. Bone. 2006;38:497–508. doi: 10.1016/j.bone.2005.10.003. [DOI] [PubMed] [Google Scholar]
42.Jacome-Galarza C.E., Lee S.K., Lorenzo J.A., Aguila H.L. Parathyroid hormone regulates the distribution and osteoclastogenic potential of hematopoietic progenitors in the bone marrow. J Bone Miner Res. 2011;26:1207–1216. doi: 10.1002/jbmr.324. [DOI] [PMC free article] [PubMed] [Google Scholar]
43.Cheng Y.H., Chitteti B.R., Streicher D.A., Morgan J.A., Rodriguez-Rodriguez S., Carlesso N., Srour E.F., Kacena M.A. Impact of maturational status on the ability of osteoblasts to enhance the hematopoietic function of stem and progenitor cells. J Bone Miner Res. 2011;26:1111–1121. doi: 10.1002/jbmr.302. [DOI] [PMC free article] [PubMed] [Google Scholar]
44.Gonzalo J.A., Lloyd C.M., Peled A., Delaney T., Coyle A.J., Gutierrez-Ramos J.C. Critical involvement of the chemotactic axis CXCR4/stromal cell-derived factor-1 alpha in the inflammatory component of allergic airway disease. J Immunol. 2000;165:499–508. doi: 10.4049/jimmunol.165.1.499. [DOI] [PubMed] [Google Scholar]
45.Gupta S.K., Pillarisetti K., Aiyar N. CXCR4 undergoes complex lineage and inducing agent-dependent dissociation of expression and functional responsiveness to SDF-1alpha during myeloid differentiation. J Leukocyte Biol. 2001;70:431–438. [PubMed] [Google Scholar]
46.Förster R., Kremmer E., Schubel A., Breitfeld D., Kleinschmidt A., Nerl C., Bernhardt G., Lipp M. Intracellular and surface expression of the HIV-1 coreceptor CXCR4/fusin on various leukocyte subsets: rapid internalization and recycling upon activation. J Immunology. 1998;160:1522–1531. [PubMed] [Google Scholar]
47.Hendrix C.W., Flexner C., MacFarland R.T., Giandomenico C., Fuchs E.J., Redpath E., Bridger G., Henson G.W. Pharmacokinetics and safety of AMD-3100, a novel antagonist of the CXCR-4 chemokine receptor, in human volunteers. Antimicrob Agents Chemother. 2000;44:1667–1673. doi: 10.1128/aac.44.6.1667-1673.2000. [DOI] [PMC free article] [PubMed] [Google Scholar]
48.D'Appuzzo M., Rolink A., Loetscher M., Hoxie J.A., Clark-Lewis I., Melchers F., Baggiolini M., Moser M. The chemokine SDF-1, stromal cell-derived factor 1, attracts early stage B cell precursors via the chemokine receptor CXCR4. Eur J Immunol. 1997;27:1788–1793. doi: 10.1002/eji.1830270729. [DOI] [PubMed] [Google Scholar]
49.Fedyk E.R., Ryyan D.H., Ritterman I., Springer T.A. Maturation decreases responsiveness of human bone marrow B lineage cells to stromal-derived factor 1 (SDF-1) J Leukocyte Biol. 1999;66:667–673. doi: 10.1002/jlb.66.4.667. [DOI] [PubMed] [Google Scholar]
50.Nagasawa T., Hirota S., Tachibana K., Takakura N., Nishikawa S., Kitamura Y., Yoshida N., Kikutani H., Kishimoto T. Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1. Nature. 1996;382:635–638. doi: 10.1038/382635a0. [DOI] [PubMed] [Google Scholar]
51.Ma Q., Jones D., Borghesani P.R., Segal R.A., Nagasawa T., Kishimoto T., Bronson R.T., Springer T.A. Impaired B-lymphopoiesis, myelopoiesis, and derailed cerebellar neuron migration in CXCR4- and SDF-1-deficient mice. Proc Natl Acad Sci USA. 1998;95:9448–9453. doi: 10.1073/pnas.95.16.9448. [DOI] [PMC free article] [PubMed] [Google Scholar]
52.Nagasawa T., Kikutani H., Kishimoto T. Molecular cloning and structure of a pre-B-cell growth-stimulating factor. Proc Natl Acad Sci USA. 1994;91:2305–2309. doi: 10.1073/pnas.91.6.2305. [DOI] [PMC free article] [PubMed] [Google Scholar]
53.Kopf M., Baumann H., Freer G., Freudenberg M., Lamers M., Kishimoto T., Zinkernagel R., Bluethmann H., Köhler G. Impaired immune and acute-phase responses in interleukin-6-deficient mice. Nature. 1994;368:339–342. doi: 10.1038/368339a0. [DOI] [PubMed] [Google Scholar]
54.Zhu J., Garrett R., Jung Y., Zhang Y., Kim N., Wang J., Joe G.J., Hexner E., Choi Y., Taichman R.S., Emerson S.G. Osteoblasts support B-lymphocyte commitment and differentiation from hematopoietic stem cells. Blood. 2007;109:3706–3712. doi: 10.1182/blood-2006-08-041384. [Erratum appeared in Blood 2007 Jul 1;110(1):17] [DOI] [PubMed] [Google Scholar]
55.Wu J.Y., Purton L.E., Rodda S.J., Chen M., Weinstein L.S., McMahon A.P., Scadden D.T., Kronenberg H.M. Osteoblastic regulation of B lymphopoiesis is mediated by Gs{alpha}-dependent signaling pathways. Proc Natl Acad Sci USA. 2008;105:16976–16981. doi: 10.1073/pnas.0802898105. [DOI] [PMC free article] [PubMed] [Google Scholar]
56.Aiuti A., Webb I.J., Bleul C., Springer T., Gutierrez-Ramos J.C. The chemokine SDF-1 is a chemoattractant for human CD34+ hematopoietic progenitor cells and provides a new mechanism to explain the mobilization of CD34+ progenitors to peripheral blood. J Exp Med. 1997;185:111–120. doi: 10.1084/jem.185.1.111. [DOI] [PMC free article] [PubMed] [Google Scholar]
57.Mohle R., Bautz F., Rafii S., Moore J., Brugger W., Kanz L. The chemokine receptor CXCR-4 is expressed on CD34+ hematopoietic progenitors and leukemic cells and mediates transendothelial migration induced by stromal cell-derived factor-1. Blood. 1998;91:4523–4530. [PubMed] [Google Scholar]
58.Rodríguez M.C., Bernad A., Aracil M. Interleukin-6 deficiency affects bone marrow stromal precursors, resulting in defective hematopoietic support. Blood. 2004;103:3349–3354. doi: 10.1182/blood-2003-10-3438. [DOI] [PubMed] [Google Scholar]
59.Bernad A., Kopf M., Kulbacki R., Weich N., Koehler G., Gutierrez-Ramos J.C. Interleukin-6 is required in vivo for the regulation of stem cells and committed progenitors of the hematopoietic system. Immunity. 1994;1:725–731. doi: 10.1016/s1074-7613(94)80014-6. [DOI] [PubMed] [Google Scholar]
60.Amara A., Lorthioir O., Valenzuela A., Magerus A., Thelen M., Montes M., Virelizier J.L., Delepierre M., Baleux F., Lortat-Jacob H., Arenzana-Seisdedos F. Stromal cell-derived factor-1alpha associates with heparan sulfates through the first beta-strand of the chemokine. J Biol Chem. 1999;274:23916–23925. doi: 10.1074/jbc.274.34.23916. [DOI] [PubMed] [Google Scholar]
61.Mbemba E., Gluckman J.C., Gattegno L. Glycan and glycosaminoglycan binding properties of stromal cell-derived factor (SDF)-1alpha. Glycobiology. 2000;10:21–29. doi: 10.1093/glycob/10.1.21. [DOI] [PubMed] [Google Scholar]
62.Netelenbos T., Zuijderduin S., Van Den Born J., Kessler F.L., Zweegman S., Huijgens P.C., Dräger A.M. Proteoglycans guide SDF-1-induced migration of hematopoietic progenitor cells. J Leukocyte Biol. 2002;72:353–362. [PubMed] [Google Scholar]
63.Netelenbos T., van den Born J., Kessler F.L., Zweegman S., Merle P.A., van Oostveen J.W., Zwaginga J.J., Huijgens P.C., Dräger A.M. Proteoglycans on bone marrow endothelial cells bind and present SDF-1 towards hematopoietic progenitor cells. Leukemia. 2003;17:175–184. doi: 10.1038/sj.leu.2402738. [DOI] [PubMed] [Google Scholar]
64.Santiago B., Baleux F., Paleo P., Gutiérrez-Cañas I., Ramírez J.C., Arenzana-Seisdedos F., Pablos J.L. CXCL12 is displayed by rheumatoid endothelial cells through its basic amino-terminal motif on heparan sulfate proteoglycans. Arthritis Res Ther. 2006;8:R43. doi: 10.1186/ar1900. [DOI] [PMC free article] [PubMed] [Google Scholar]
65.Huber B.C., Brunner S., Segeth A., Nathan P., Fischer R., Zaruba M.M., Vallaster M., Theiss H.D., David R., Gerbitz A., Franz W.M. Parathyroid hormone is a DPP-IV inhibitor and increases SDF-1-driven homing of CXCR4+ stem cells into the ischaemic heart. Cardiovasc Res. 2011;90:529–537. doi: 10.1093/cvr/cvr014. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supplemental Table S1

mmc1.doc^{(37.5KB, doc)}

Supplemental Figure S1

mmc2.pdf^{(248.5KB, pdf)}

Supplemental Figure S2

mmc3.pdf^{(93.3KB, pdf)}

[bib1] 1.Kousteni S., Bilezikian J.P. In: Principles of Bone Biology. ed 3. Bilezikian J.P., Raisz L.G., Martin T.J., editors. 2008. Cellular actions of parathyroid hormone; pp. 639–656. [Google Scholar]

[bib2] 2.Calvi L.M., Adams G.B., Welbrecht K.W., Weber J.M., Olson D.P., Knight M.C., Martin R.P., Schipani E., Divieti P., Bringhurst F.R., Milner L.A., Kronenberg H.M., Scadden D.T. Osteoblastic cells regulate the haematopoietic stem cell niche. Nature. 2003;425:841–846. doi: 10.1038/nature02040. [DOI] [PubMed] [Google Scholar]

[bib3] 3.Brunner S., Zaruba M., Huber B., David R., Vallaster M., Assmann G., Mueller-Hoecker J., Franz W.M. Parathyroid hormone effectively induces mobilization of progenitor cells without depletion of bone marrow. Exp Hematol. 2008;36:1157–1166. doi: 10.1016/j.exphem.2008.03.014. [DOI] [PubMed] [Google Scholar]

[bib4] 4.Adams G.B., Martin R.P., Alley I.R., Chabner K.T., Cohen K.S., Calvi L.M., Kronenberg H.M., Scadden D.T. Therapeutic targeting of a stem cell niche. Nat Biotechnol. 2007;25:238–243. doi: 10.1038/nbt1281. [Erratum appeared in Nat Biotechnol 2007, 25:944, and in Nat Biotechnol 2008, 26:241] [DOI] [PubMed] [Google Scholar]

[bib5] 5.Ballen K.K., Shpall E.J., Avigan D., Yeap B.Y., Fisher D.C., McDermott K., Dey B.R., Attar E., McAfee S., Konopleva M., Antin J.H., Spitzer T.R. Phase I trial of parathyroid hormone to facilitate stem cell mobilization. Biol Blood Marrow Transplant. 2007;13:838–843. doi: 10.1016/j.bbmt.2007.03.007. [DOI] [PubMed] [Google Scholar]

[bib6] 6.McCauley L.K., Rosol T.J., Merryman J.I., Capen C.C. Parathyroid hormone-related protein binding to human T-cell lymphotropic virus type-I-infected lymphocytes. Endocrinology. 1992;130:300–306. doi: 10.1210/endo.130.1.1309334. [DOI] [PubMed] [Google Scholar]

[bib7] 7.Terauchi M., Li J.Y., Bedi B., Baek K.H., Tawfeek H., Galley S., Gilbert L., Nanes M.S., Zayzafoon M., Guldberg R., Lamar D.L., Singer M.A., Lane T.F., Kronenberg H.M., Pacifici R. T lymphocytes amplify the anabolic activity of parathyroid hormone through Wnt10b signaling. Cell Metab. 2009;10:229–240. doi: 10.1016/j.cmet.2009.07.010. [DOI] [PMC free article] [PubMed] [Google Scholar]

[bib8] 8.Li X., Liu H., Qin L., Tamasi J., Bergenstock M., Shapses S., Feyen J.H., Notterman D.A., Partridge N.C. Determination of dual effects of parathyroid hormone on skeletal gene expression in vivo by microarray and network analysis. J Biol Chem. 2007;282:33086–33097. doi: 10.1074/jbc.M705194200. [DOI] [PubMed] [Google Scholar]

[bib9] 9.Ma Y.L., Cain R.L., Halladay D.L., Yang X., Zeng Q., Miles R.R., Chandrasekhar S., Martin T.J., Onyia J.E. Catabolic effects of continuous human PTH (1–38) in vivo is associated with sustained stimulation of RANKL and inhibition of osteoprotegerin and gene-associated bone formation. Endocrinology. 2001;142:4047–4054. doi: 10.1210/endo.142.9.8356. [DOI] [PubMed] [Google Scholar]

[bib10] 10.Locklin R.M., Khosla S., Turner R.T., Riggs B.L. Mediators of biphasic responses of bone to intermittent and continuously administered parathyroid hormone. J Cell Biochem. 2003;89:180–190. doi: 10.1002/jcb.10490. [DOI] [PubMed] [Google Scholar]

[bib11] 11.Silvestrini G., Ballanti P., Leopizzi M., Gualtieri N., Sardella D., Monnazzi P., Simeoni S., Sebastiani M., Bonucci E., Patacchioli F.R. Effects of the administration of corticosterone, parathyroid hormone, or both, and of their withdrawal, on rat bone and cartilage histomorphometric parameters, and on osteoprotegerin and RANKL mRNA expression and proteins. J Mol Histol. 2007;38:215–226. doi: 10.1007/s10735-007-9090-9. [DOI] [PubMed] [Google Scholar]

[bib12] 12.Lee S.K., Lorenzo J.A. Parathyroid hormone stimulates TRANCE and inhibits osteoprotegerin messenger ribonucleic acid expression in murine bone marrow cultures: correlation with osteoclast-like cell formation. J Bone Miner Res. 1999;140:3552–3561. doi: 10.1210/endo.140.8.6887. [DOI] [PubMed] [Google Scholar]

[bib13] 13.Pirih F.Q., Michalski M.N., Cho S.W., Koh A.J., Berry J.E., Ghaname E., Kamarajan P., Bonnelye E., Ross C.W., Kapila Y.L., Jurdic P., McCauley L.K. Parathyroid hormone mediates hematopoietic cell expansion through interleukin-6. PLoS One. 2010;5:e13657. doi: 10.1371/journal.pone.0013657. [DOI] [PMC free article] [PubMed] [Google Scholar]

[bib14] 14.Liu Y.J., Lu S.H., Xu B., Yang R.C., Ren Q., Liu B., Li B., Lu M., Yan F.Y., Han Z.B., Han Z.C. Hemangiopoietin, a novel human growth factor for the primitive cells of both hematopoietic and endothelial cell lineages. Blood. 2004;103:4449–4456. doi: 10.1182/blood-2003-06-1825. [DOI] [PubMed] [Google Scholar]

[bib15] 15.Xu Z.L., Zhou B., Cong X.L., Liu Y.J., Xu B., Li Y.H., Gu J., Han Z.C. Hemangiopoietin supports animal survival and accelerates hematopoietic recovery of chemotherapy-suppressed mice. Eur J Haematol. 2007;79:477–485. doi: 10.1111/j.1600-0609.2007.00969.x. [DOI] [PubMed] [Google Scholar]

[bib16] 16.Xu Z.S., Liu Y.J., Lv L.L., Han Z.B., He R., Lu S.H., Wang T., Xu B., Chen Z.Z., Han Z.C. Bone marrow stromal cells transduced with human hemangiopoietin gene support hematopoiesis in vitro. Haematologica. 2005;90:157–165. [PubMed] [Google Scholar]

[bib17] 17.Merberg D.M., Fitz L.J., Temple P., Giannotti J., Murtha P., Fitzgerald M., Scaltreto H., Kelleher K., Preissner K., Kriz R., Jacobs K., Turner K. In: Biology of Vitronectins and Their Receptors: Proceedings of the First International Vitronectin Workshop, Rauischholzhausen Castle, Marburg, Germany, 25–28 August, 1993. Preissner K.T., Rosenblatt S., Kost C., Wegerhoff J., Mosher D.F., editors. Elsevier; Philadelphia: 1992. A comparison of vitronectin and megakaryocyte stimulating factor; pp. 45–53. [Google Scholar]

[bib18] 18.Greenberg S.M., Kuter D.J., Rosenberg R.D. In vitro stimulation of megakaryocyte maturation by megakaryocyte stimulatory factor. J Biol Chem. 1987;262:3269–3277. [PubMed] [Google Scholar]

[bib19] 19.Tayrien G., Rosenberg R.D. Purification and properties of a megakaryocyte stimulatory factor present both in the serum-free conditioned medium of human embryonic kidney cells and in thrombocytopenic plasma. J Biol Chem. 1987;262:3262–3268. [PubMed] [Google Scholar]

[bib20] 20.Novince C.M., Koh A.J., Marchesan J.T., McCauley L.K. Proteoglycan-4: a novel gene regulating parathyroid hormone actions in bone anabolism and hematopoiesis (abstract 1186): ASBMR 31st Annual Meeting 1001–1300. J Bone Miner Res. 2009;24:S56–S57. [Google Scholar]

[bib21] 21.Novince C.M., Michalski M.N., Sinder B.P., Entezami P., Koh A.J., Eber M.J., Pettway G.J., Rosol T.J., Wronski T.J., Kozloff K.M., McCauley L.K. J Bone Miner Res. 2011. Proteoglycan 4: a dynamic regulator of skeletogenesis and PTH skeletal anabolism. [DOI] [PMC free article] [PubMed] [Google Scholar]

[bib22] 22.Ikegawa S., Sano M., Koshizuka Y., Nakamura Y. Isolation, characterization and mapping of the mouse and human PRG4 (proteoglycan 4) genes. Cytogenet Genome Res. 2000;90:291–297. doi: 10.1159/000056791. [DOI] [PubMed] [Google Scholar]

[bib23] 23.Rhee D.K., Marcelino J., Baker M., Gong Y., Smits P., Lefebvre V., Jay G.D., Stewart M., Wang H., Warman M.L., Carpten J.D. The secreted glycoprotein lubricin protects cartilage surfaces and inhibits synovial cell overgrowth. J Clin Invest. 2005;115:622–631. doi: 10.1172/JCI200522263. [DOI] [PMC free article] [PubMed] [Google Scholar]

[bib24] 24.Schumacher B.L., Block J.A., Schmid T.M., Aydelotte M.B., Kuettner K.E. A novel proteoglycan synthesized and secreted by chondrocytes of the superficial zone of articular cartilage. Arch Biochem Biophys. 1994;311:144–152. doi: 10.1006/abbi.1994.1219. [DOI] [PubMed] [Google Scholar]

[bib25] 25.Marcelino J., Carpten J.D., Suwairi W.M., Gutierrez O.M., Schwartz S., Robbins C., Sood R., Makalowska I., Baxevanis A., Johnstone B., Laxer R.M., Zemel L., Kim C.A., Herd J.K., Ihle J., Williams C., Johnson M., Raman V., Alonso L.G., Brunoni D., Gerstein A., Papadopoulos N., Bahabri S.A., Trent J.M., Warman M.L. CACP, encoding a secreted proteoglycan, is mutated in camptodactyly-arthropathy-coxa vara-pericarditis syndrome. Nat Genet. 1999;23:319–322. doi: 10.1038/15496. [DOI] [PubMed] [Google Scholar]

[bib26] 26.Schmittgen T.D., Livak K.J. Analyzing real-time PCR data by the comparative CT method. Nat Protocols. 2008;3:1101–1108. doi: 10.1038/nprot.2008.73. [DOI] [PubMed] [Google Scholar]

[bib27] 27.McCauley L.K., Koh A.J., Beecher C.A., Cui Y., Decker J.D., Francheschi R.T. Effects of differentiation and transforming growth factor beta on PTH/PTHrP receptor mRNA levels in MC3T3-E1 cells. J Bone Miner Res. 1995;10:1243–1255. doi: 10.1002/jbmr.5650100815. [DOI] [PubMed] [Google Scholar]

[bib28] 28.Kopf M., Ramsay A., Brombacher F., Baumann H., Freer G., Galanos C., Gutierrez-Ramos J.C., Köhler G. Pleiotropic defects of IL-6-deficient mice including early hematopoiesis: T and B cell function, and acute phase responses. Ann N Y Acad Sci. 1985;21:308–318. doi: 10.1111/j.1749-6632.1995.tb32335.x. [DOI] [PubMed] [Google Scholar]

[bib29] 29.Ikebuchi K., Wong G.G., Clark S.C., Ihle J.N., Hirai Y., Ogawa M. Interleukin 6 enhancement of interleukin 3-dependent proliferation of multipotential hemopoietic progenitors. Proc Natl Acad Sci USA. 1987;84:9035–9039. doi: 10.1073/pnas.84.24.9035. [DOI] [PMC free article] [PubMed] [Google Scholar]

[bib30] 30.Imai T., Koike K., Kubo T., Kikuchi T., Amano Y., Takagi M., Okumura N., Nakahata T. Interleukin-6 supports human megakaryocytic proliferation and differentiation in vitro. Blood. 1991;78:1969–1974. [PubMed] [Google Scholar]

[bib31] 31.Hill R.J., Warren M.K., Stenberg P., Levin J., Corash L., Drummond R., Baker G., Levin F., Mok Y. Stimulation of megakaryocytopoiesis in mice by human recombinant interleukin-6. Blood. 1991;77:42–48. [PubMed] [Google Scholar]

[bib32] 32.Greenfield E.M., Gornik S.A., Horowitz M.C., Donahue H.J., Shaw S.M. Regulation of cytokine expression in osteoblasts by parathyroid hormone: rapid stimulation of interleukin-6 and leukemia inhibitory factor mRNA. J Bone Miner Res. 1993;8:1163–1171. doi: 10.1002/jbmr.5650081003. [DOI] [PubMed] [Google Scholar]

[bib33] 33.Onyia J.E., Bidwell J., Herring J., Hulman J., Hock J.M. In vivo, human parathyroid hormone fragment (hPTH 1-34) transiently stimulates immediate early response gene expression, but not proliferation, in trabecular bone cells of young rats. Bone. 1995;17:479–484. doi: 10.1016/8756-3282(95)00332-2. [DOI] [PubMed] [Google Scholar]

[bib34] 34.Pollock J.H., Blaha M.J., Lavish S.A., Stevenson S., Greenfield E.M. In vivo demonstration that parathyroid hormone and parathyroid hormone-related protein stimulate expression by osteoblasts of interleukin-6 and leukemia inhibitory factor. J Bone Miner Res. 1996;11:754–759. doi: 10.1002/jbmr.5650110606. [DOI] [PubMed] [Google Scholar]

[bib35] 35.Murone M., Carpenter D.A., de Sauvage F.J. Hematopoietic deficiencies in c-mpl and TPO knockout mice. Stem Cells. 1998;16:1–6. doi: 10.1002/stem.160001. [DOI] [PubMed] [Google Scholar]

[bib36] 36.Peled A., Petit I., Kollet O., Magid M., Ponomaryov T., Byk T., Nagler A., Ben-Hur H., Many A., Shultz L., Lider O., Alon R., Zipori D., Lapidot T. Dependence of human stem cell engraftment and repopulation of NOD/SCID mice on CXCR4. Science. 1999;283:845–848. doi: 10.1126/science.283.5403.845. [DOI] [PubMed] [Google Scholar]

[bib37] 37.Jo D.Y., Rafii S., Hamada T., Moore M.A. Chemotaxis of primitive hematopoietic cells in response to stromal cell-derived factor-1. J Clin Invest. 2000;105:101–111. doi: 10.1172/JCI7954. [DOI] [PMC free article] [PubMed] [Google Scholar]

[bib38] 38.Wang J.F., Liu Z.Y., Groopman J.E. The alpha-chemokine receptor CXCR4 is expressed on the megakaryocytic lineage from progenitor to platelets and modulates migration and adhesion. Blood. 1998;92:756–764. [PubMed] [Google Scholar]

[bib39] 39.Suratt B.T., Petty J.M., Young S.K., Malcom K.C., Lieber J.A., Nick J.A., Gonzalo J.A., Henson P.M., Worthen G.S. Role of the CXCR4/SDF-1 chemokine axis in circulating neutrophil homeostasis. Blood. 2004;104:565–571. doi: 10.1182/blood-2003-10-3638. [DOI] [PubMed] [Google Scholar]

[bib40] 40.Ma Q., Jones D., Springer T.A. The chemokine receptor CXCR4 is required for the retention of B lineage and granulocytic precursors within the bone marrow microenvironment. Immunity. 1999;10:463–471. doi: 10.1016/s1074-7613(00)80046-1. [DOI] [PubMed] [Google Scholar]

[bib41] 41.Jung Y., Wang J., Schneider A., Sun Y.X., Koh-Paige A.J., Osman N.I., McCauley L.K., Taichman R.S. Regulation of SDF-1 (CXCL12) production by osteoblasts in the hematopoietic microenvironment and a possible mechanism for stem cell homing. Bone. 2006;38:497–508. doi: 10.1016/j.bone.2005.10.003. [DOI] [PubMed] [Google Scholar]

[bib42] 42.Jacome-Galarza C.E., Lee S.K., Lorenzo J.A., Aguila H.L. Parathyroid hormone regulates the distribution and osteoclastogenic potential of hematopoietic progenitors in the bone marrow. J Bone Miner Res. 2011;26:1207–1216. doi: 10.1002/jbmr.324. [DOI] [PMC free article] [PubMed] [Google Scholar]

[bib43] 43.Cheng Y.H., Chitteti B.R., Streicher D.A., Morgan J.A., Rodriguez-Rodriguez S., Carlesso N., Srour E.F., Kacena M.A. Impact of maturational status on the ability of osteoblasts to enhance the hematopoietic function of stem and progenitor cells. J Bone Miner Res. 2011;26:1111–1121. doi: 10.1002/jbmr.302. [DOI] [PMC free article] [PubMed] [Google Scholar]

[bib44] 44.Gonzalo J.A., Lloyd C.M., Peled A., Delaney T., Coyle A.J., Gutierrez-Ramos J.C. Critical involvement of the chemotactic axis CXCR4/stromal cell-derived factor-1 alpha in the inflammatory component of allergic airway disease. J Immunol. 2000;165:499–508. doi: 10.4049/jimmunol.165.1.499. [DOI] [PubMed] [Google Scholar]

[bib45] 45.Gupta S.K., Pillarisetti K., Aiyar N. CXCR4 undergoes complex lineage and inducing agent-dependent dissociation of expression and functional responsiveness to SDF-1alpha during myeloid differentiation. J Leukocyte Biol. 2001;70:431–438. [PubMed] [Google Scholar]

[bib46] 46.Förster R., Kremmer E., Schubel A., Breitfeld D., Kleinschmidt A., Nerl C., Bernhardt G., Lipp M. Intracellular and surface expression of the HIV-1 coreceptor CXCR4/fusin on various leukocyte subsets: rapid internalization and recycling upon activation. J Immunology. 1998;160:1522–1531. [PubMed] [Google Scholar]

[bib47] 47.Hendrix C.W., Flexner C., MacFarland R.T., Giandomenico C., Fuchs E.J., Redpath E., Bridger G., Henson G.W. Pharmacokinetics and safety of AMD-3100, a novel antagonist of the CXCR-4 chemokine receptor, in human volunteers. Antimicrob Agents Chemother. 2000;44:1667–1673. doi: 10.1128/aac.44.6.1667-1673.2000. [DOI] [PMC free article] [PubMed] [Google Scholar]

[bib48] 48.D'Appuzzo M., Rolink A., Loetscher M., Hoxie J.A., Clark-Lewis I., Melchers F., Baggiolini M., Moser M. The chemokine SDF-1, stromal cell-derived factor 1, attracts early stage B cell precursors via the chemokine receptor CXCR4. Eur J Immunol. 1997;27:1788–1793. doi: 10.1002/eji.1830270729. [DOI] [PubMed] [Google Scholar]

[bib49] 49.Fedyk E.R., Ryyan D.H., Ritterman I., Springer T.A. Maturation decreases responsiveness of human bone marrow B lineage cells to stromal-derived factor 1 (SDF-1) J Leukocyte Biol. 1999;66:667–673. doi: 10.1002/jlb.66.4.667. [DOI] [PubMed] [Google Scholar]

[bib50] 50.Nagasawa T., Hirota S., Tachibana K., Takakura N., Nishikawa S., Kitamura Y., Yoshida N., Kikutani H., Kishimoto T. Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1. Nature. 1996;382:635–638. doi: 10.1038/382635a0. [DOI] [PubMed] [Google Scholar]

[bib51] 51.Ma Q., Jones D., Borghesani P.R., Segal R.A., Nagasawa T., Kishimoto T., Bronson R.T., Springer T.A. Impaired B-lymphopoiesis, myelopoiesis, and derailed cerebellar neuron migration in CXCR4- and SDF-1-deficient mice. Proc Natl Acad Sci USA. 1998;95:9448–9453. doi: 10.1073/pnas.95.16.9448. [DOI] [PMC free article] [PubMed] [Google Scholar]

[bib52] 52.Nagasawa T., Kikutani H., Kishimoto T. Molecular cloning and structure of a pre-B-cell growth-stimulating factor. Proc Natl Acad Sci USA. 1994;91:2305–2309. doi: 10.1073/pnas.91.6.2305. [DOI] [PMC free article] [PubMed] [Google Scholar]

[bib53] 53.Kopf M., Baumann H., Freer G., Freudenberg M., Lamers M., Kishimoto T., Zinkernagel R., Bluethmann H., Köhler G. Impaired immune and acute-phase responses in interleukin-6-deficient mice. Nature. 1994;368:339–342. doi: 10.1038/368339a0. [DOI] [PubMed] [Google Scholar]

[bib54] 54.Zhu J., Garrett R., Jung Y., Zhang Y., Kim N., Wang J., Joe G.J., Hexner E., Choi Y., Taichman R.S., Emerson S.G. Osteoblasts support B-lymphocyte commitment and differentiation from hematopoietic stem cells. Blood. 2007;109:3706–3712. doi: 10.1182/blood-2006-08-041384. [Erratum appeared in Blood 2007 Jul 1;110(1):17] [DOI] [PubMed] [Google Scholar]

[bib55] 55.Wu J.Y., Purton L.E., Rodda S.J., Chen M., Weinstein L.S., McMahon A.P., Scadden D.T., Kronenberg H.M. Osteoblastic regulation of B lymphopoiesis is mediated by Gs{alpha}-dependent signaling pathways. Proc Natl Acad Sci USA. 2008;105:16976–16981. doi: 10.1073/pnas.0802898105. [DOI] [PMC free article] [PubMed] [Google Scholar]

[bib56] 56.Aiuti A., Webb I.J., Bleul C., Springer T., Gutierrez-Ramos J.C. The chemokine SDF-1 is a chemoattractant for human CD34+ hematopoietic progenitor cells and provides a new mechanism to explain the mobilization of CD34+ progenitors to peripheral blood. J Exp Med. 1997;185:111–120. doi: 10.1084/jem.185.1.111. [DOI] [PMC free article] [PubMed] [Google Scholar]

[bib57] 57.Mohle R., Bautz F., Rafii S., Moore J., Brugger W., Kanz L. The chemokine receptor CXCR-4 is expressed on CD34+ hematopoietic progenitors and leukemic cells and mediates transendothelial migration induced by stromal cell-derived factor-1. Blood. 1998;91:4523–4530. [PubMed] [Google Scholar]

[bib58] 58.Rodríguez M.C., Bernad A., Aracil M. Interleukin-6 deficiency affects bone marrow stromal precursors, resulting in defective hematopoietic support. Blood. 2004;103:3349–3354. doi: 10.1182/blood-2003-10-3438. [DOI] [PubMed] [Google Scholar]

[bib59] 59.Bernad A., Kopf M., Kulbacki R., Weich N., Koehler G., Gutierrez-Ramos J.C. Interleukin-6 is required in vivo for the regulation of stem cells and committed progenitors of the hematopoietic system. Immunity. 1994;1:725–731. doi: 10.1016/s1074-7613(94)80014-6. [DOI] [PubMed] [Google Scholar]

[bib60] 60.Amara A., Lorthioir O., Valenzuela A., Magerus A., Thelen M., Montes M., Virelizier J.L., Delepierre M., Baleux F., Lortat-Jacob H., Arenzana-Seisdedos F. Stromal cell-derived factor-1alpha associates with heparan sulfates through the first beta-strand of the chemokine. J Biol Chem. 1999;274:23916–23925. doi: 10.1074/jbc.274.34.23916. [DOI] [PubMed] [Google Scholar]

[bib61] 61.Mbemba E., Gluckman J.C., Gattegno L. Glycan and glycosaminoglycan binding properties of stromal cell-derived factor (SDF)-1alpha. Glycobiology. 2000;10:21–29. doi: 10.1093/glycob/10.1.21. [DOI] [PubMed] [Google Scholar]

[bib62] 62.Netelenbos T., Zuijderduin S., Van Den Born J., Kessler F.L., Zweegman S., Huijgens P.C., Dräger A.M. Proteoglycans guide SDF-1-induced migration of hematopoietic progenitor cells. J Leukocyte Biol. 2002;72:353–362. [PubMed] [Google Scholar]

[bib63] 63.Netelenbos T., van den Born J., Kessler F.L., Zweegman S., Merle P.A., van Oostveen J.W., Zwaginga J.J., Huijgens P.C., Dräger A.M. Proteoglycans on bone marrow endothelial cells bind and present SDF-1 towards hematopoietic progenitor cells. Leukemia. 2003;17:175–184. doi: 10.1038/sj.leu.2402738. [DOI] [PubMed] [Google Scholar]

[bib64] 64.Santiago B., Baleux F., Paleo P., Gutiérrez-Cañas I., Ramírez J.C., Arenzana-Seisdedos F., Pablos J.L. CXCL12 is displayed by rheumatoid endothelial cells through its basic amino-terminal motif on heparan sulfate proteoglycans. Arthritis Res Ther. 2006;8:R43. doi: 10.1186/ar1900. [DOI] [PMC free article] [PubMed] [Google Scholar]

[bib65] 65.Huber B.C., Brunner S., Segeth A., Nathan P., Fischer R., Zaruba M.M., Vallaster M., Theiss H.D., David R., Gerbitz A., Franz W.M. Parathyroid hormone is a DPP-IV inhibitor and increases SDF-1-driven homing of CXCR4+ stem cells into the ischaemic heart. Cardiovasc Res. 2011;90:529–537. doi: 10.1093/cvr/cvr014. [DOI] [PubMed] [Google Scholar]

PERMALINK

Proteoglycan 4, a Novel Immunomodulatory Factor, Regulates Parathyroid Hormone Actions on Hematopoietic Cells

Chad M Novince

Amy J Koh

Megan N Michalski

Julie T Marchesan

Jason Wang

Younghun Jung

Janice E Berry

Matthew R Eber

Thomas J Rosol

Russell S Taichman

Laurie K McCauley

Abstract

Table 1.

Materials and Methods

C57BL/6 Wild-Type Mice, Single PTH Administration

Primary Calvarial Osteoblastic Cell Cultures, Single PTH Administration

Background of Prg4−/− Mutant Mice

Prg4−/− Mutant Mice, Single PTH Administration

Prg4−/− Mutant Mice, 6 Weeks Daily Intermittent PTH Administration

Quantitative Real-Time PCR

Complete Blood Counts

Flow Cytometry

Histomorphometry

Bone Marrow Biochemical Studies

Statistical Analysis

Results

Single PTH Administration Increases Prg4 mRNA Levels in Bone

Figure 1.

Bone Marrow, Liver, and Spleen Morphology

Figure 2.

Bone Marrow IL-6, Thrombopoietin, and SDF-1 mRNA in Prg4−/− Mice

Figure 3.

Prg4−/− Mice Have Altered Immune Cell Populations, Normalized by PTH

Figure 4.

Figure 5.

Prg4−/− Mice Have Decreased Expansion of Marrow HPCs Induced by PTH

Figure 6.

Marrow Megakaryopoiesis Is Similar in Prg4−/− and Prg4+/+ Mice

Prg4−/− Mice Have Altered Marrow IL-6 mRNA and SDF-1 Protein

Figure 7.

Discussion

Acknowledgments

Footnotes

Supplementary data

References

Associated Data

Supplementary Materials

ACTIONS

PERMALINK

RESOURCES

Similar articles

Cited by other articles

Links to NCBI Databases

Background of Prg4^−/− Mutant Mice

Prg4^−/− Mutant Mice, Single PTH Administration

Prg4^−/− Mutant Mice, 6 Weeks Daily Intermittent PTH Administration

Bone Marrow IL-6, Thrombopoietin, and SDF-1 mRNA in Prg4^−/− Mice

Prg4^−/− Mice Have Altered Immune Cell Populations, Normalized by PTH

Prg4^−/− Mice Have Decreased Expansion of Marrow HPCs Induced by PTH

Marrow Megakaryopoiesis Is Similar in Prg4^−/− and Prg4^+/+ Mice

Prg4^−/− Mice Have Altered Marrow IL-6 mRNA and SDF-1 Protein